ViiV starts Phase III trial comparing Selzentry with Truvada
This article was originally published in Scrip
Executive Summary
ViiV Healthcare, the GlaxoSmithKline/Pfizer joint venture focused on HIV, has begun a Phase III study comparing maraviroc (Celsentri/Selzentry) to emtricitabine/tenofovir (Truvada), both in combination with darunavir/ritonavir. The 96-week trial will evaluate a two-drug versus three-drug once-daily regimen for the treatment of antiretroviral-naive patients infected with CCR5-tropic HIV-1.